Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wine preparation, dews preparations, and two Chinese medicine preparation production lines. Its products are used for the treatment of… Read more
Guiyang Xintian Pharmaceutical Co Ltd (002873) - Total Liabilities
Latest total liabilities as of September 2025: CN¥829.62 Million CNY
Based on the latest financial reports, Guiyang Xintian Pharmaceutical Co Ltd (002873) has total liabilities worth CN¥829.62 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guiyang Xintian Pharmaceutical Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guiyang Xintian Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guiyang Xintian Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ESSO THAILAND NVDR (JAV2.SG)
STU:JAV2
|
Germany | €36.69 Billion |
|
Xinjiang Winka Times Dept
SHG:603101
|
China | CN¥3.53 Billion |
|
Guangxi Fenglin Wood Industry Group Co Ltd
SHG:601996
|
China | CN¥989.72 Million |
|
Indo Count Industries Limited
NSE:ICIL
|
India | ₹19.36 Billion |
|
Alto Ingredients Inc
NASDAQ:ALTO
|
USA | $166.07 Million |
|
Legacy Housing Corp
NASDAQ:LEGH
|
USA | $36.33 Million |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
China | CN¥1.02 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Guiyang Xintian Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guiyang Xintian Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guiyang Xintian Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual total liabilities of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥755.79 Million | -5.35% |
| 2023-12-31 | CN¥798.47 Million | +11.73% |
| 2022-12-31 | CN¥714.65 Million | +12.72% |
| 2021-12-31 | CN¥633.98 Million | -10.41% |
| 2020-12-31 | CN¥707.64 Million | +88.76% |
| 2019-12-31 | CN¥374.89 Million | +15.81% |
| 2018-12-31 | CN¥323.72 Million | +38.17% |
| 2017-12-31 | CN¥234.30 Million | -13.33% |
| 2016-12-31 | CN¥270.33 Million | -0.99% |
| 2015-12-31 | CN¥273.05 Million | -1.52% |
| 2014-12-31 | CN¥277.26 Million | +24.69% |
| 2013-12-31 | CN¥222.36 Million | +40.38% |
| 2012-12-31 | CN¥158.40 Million | -- |